A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer (Q46487410)
Jump to navigation
Jump to search
scientific article published in April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer |
scientific article published in April 2008 |
Statements
1 reference
A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer (English)
1 reference
Orlando Silva
1 reference
Gilberto Lopes
1 reference
Daniel Morgenzstern
1 reference
Christopher Lobo
1 reference
Philomena Doliny
1 reference
Edgardo Santos
1 reference
Sakher Abdullah
1 reference
Umang Gautam
1 reference
Isildinha Reis
1 reference
Catherine Welsh
1 reference
Joyce Slingerland
1 reference
Judith Hurley
1 reference
Stefan Gluck
1 reference
1 April 2008
1 reference
8
1 reference
2
1 reference
162-167
1 reference